StoryFunding
Cognito Therapeutics closes $105M Series C to advance Spectris toward FDA approval and 2027 commercial launch
Cognito Therapeutics closed an oversubscribed $105 million Series C funding round led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from Apollo Health Ventures and Benvolio Group. The funding supports the company's pivotal trial data readout, FDA regulatory submission, and commercial launch preparation.
- $105M Series C raised March 2026, led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital.
- Funds support HOPE trial data readout (expected mid-2026) and regulatory submission for FDA approval.
- Preparation for commercial launch targeted for 2027, with potential expansion to other neurodegenerative diseases.